Guardant Health (NASDAQ:GH) Reaches New 1-Year High – Here’s What Happened

Shares of Guardant Health, Inc. (NASDAQ:GH) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $176.58 and last traded at $168.0250, with a volume of 700243 shares trading hands. The stock had previously closed at $152.35.

Guardant Health News Roundup

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Second-quarter revenue rose 44.3% year over year to $335.0 million, above the approximately $314 million analyst consensus. Oncology revenue increased 38% to $219.1 million, while oncology testing volume climbed 63% to approximately 104,000 tests. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: Guardant raised its 2026 revenue guidance to $1.3 billion-$1.4 billion, with the low end roughly matching Wall Street’s prior expectation. The increase signals confidence in continued demand for the company’s cancer-screening and monitoring products. Guardant Health Raises 2026 Revenue Outlook
• Positive Sentiment: The adjusted loss narrowed from a year earlier, supporting the company’s growth narrative even as it continues investing heavily to expand its testing business. Some earnings reports also characterized the quarterly EPS result as substantially better than broader consensus estimates. Guardant Health Q2 Adjusted Loss Narrows, Revenue Rises
• Neutral Sentiment: Profitability remains unresolved. Guardant still reported a quarterly loss of $0.42 per share, compared with a $0.44 loss a year earlier. One estimate-based analysis showed the loss was slightly worse than the $0.40 consensus, highlighting that revenue growth has not yet translated into sustained earnings. Guardant Health Reports Q2 Loss and Tops Revenue Estimates

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. UBS Group set a $150.00 price objective on shares of Guardant Health in a research report on Wednesday, June 24th. Canaccord Genuity Group increased their target price on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Piper Sandler set a $127.00 price target on Guardant Health in a research report on Thursday, May 21st. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Friday. Finally, Mizuho set a $200.00 price target on Guardant Health in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $172.55.

Guardant Health Stock Up 7.2%

The company’s 50 day moving average is $142.58 and its 200 day moving average is $113.03. The firm has a market capitalization of $21.65 billion, a price-to-earnings ratio of -47.89 and a beta of 1.59.

Insider Activity at Guardant Health

In related news, CEO Amirali Talasaz sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the sale, the chief executive officer directly owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the sale, the director directly owned 11,183 shares in the company, valued at $1,420,017.34. This represents a 47.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GH. World Investment Advisors acquired a new position in Guardant Health in the fourth quarter valued at about $1,664,000. Orbimed Advisors LLC acquired a new stake in Guardant Health during the first quarter worth about $40,199,000. Capricorn Fund Managers Ltd grew its stake in Guardant Health by 197.8% during the fourth quarter. Capricorn Fund Managers Ltd now owns 107,787 shares of the company’s stock worth $11,009,000 after buying an additional 71,587 shares in the last quarter. Styrax Capital LP increased its holdings in Guardant Health by 6.5% in the 1st quarter. Styrax Capital LP now owns 300,000 shares of the company’s stock valued at $27,711,000 after buying an additional 18,411 shares during the period. Finally, Caxton Associates LLP bought a new position in Guardant Health in the 1st quarter valued at about $831,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.